Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease

E.G. Quetglas, Z. Mujagic, S. Wigge, D. Keszthelyi, S. Wachten, A. Masclee, W. Reinisch

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)

Abstract

The search for biomarkers that characterize specific aspects of inflammatory bowel disease (IBD), has received substantial interest in the past years and is moving forward rapidly with the help of modern technologies. Nevertheless, there is a direct demand to identify adequate biomarkers for predicting and evaluating therapeutic response to different therapies. In this subset, pharmacogenetics deserves more attention as part of the endeavor to provide personalized medicine. The ultimate goal in this area is the adjustment of medication for a patient's specific genetic background and thereby to improve drug efficacy and safety rates. The aim of the following review is to utilize the latest knowledge on immunopathogenesis of IBD and update the findings on the field of Immunology and Genetics, to evaluate the response to the different therapies. In the present article, more than 400 publications were reviewed but finally 287 included based on design, reproducibility (or expectancy to be reproducible and translationable into humans) or already measured in humans. A few tests have shown clinical applicability. Other, i.e., genetic associations for the different therapies in IBD have not yet shown consistent or robust results. In the close future it is anticipated that this, cellular and genetic material, as well as the determination of biomarkers will be implemented in an integrated molecular diagnostic and prognostic approach to manage IBD patients.
Original languageEnglish
Pages (from-to)12519-12543
Number of pages25
JournalWorld Journal of Gastroenterology
Volume21
Issue number44
DOIs
Publication statusPublished - 28 Nov 2015

Keywords

  • Mucosal immunology
  • Biomarkers
  • Pharmacology
  • Mode of action
  • Therapeutic drug monitoring
  • TUMOR-NECROSIS-FACTOR
  • FACTOR-KAPPA-B
  • SINGLE NUCLEOTIDE POLYMORPHISMS
  • METHYLENETETRAHYDROFOLATE REDUCTASE GENE
  • LAMINA PROPRIA LYMPHOCYTES
  • ALPHA MONOCLONAL-ANTIBODY
  • ACTIVATED PROTEIN-KINASE
  • GENOME-WIDE ASSOCIATION
  • LOW-DOSE METHOTREXATE
  • REGULATORY T-CELLS

Cite this